摘要
目的 :探讨生物制剂联合化疗药物膀胱灌注预防膀胱癌术后复发的机制。方法 :对比研究白细胞介素 2 (IL 2 )和吡柔比星联合膀胱灌注与单用吡柔比星膀胱灌注前后患者血、尿肿瘤坏死因子 (TNF)和血IL 2受体的动态变化。结果 :联合膀胱灌注组的TNF和IL 2受体水平显著高于吡柔比星组 (P <0 .0 1)。结论 :联合灌注组机体的细胞免疫功能得到更好改善 ,IL 2增加肿瘤细胞对免疫反应的应答 。
Objective:To explore the effects of intravesical instillation of pirarubicin together with IL 2 on patients with bladder cancer,who had undergone surgical operation.Methods:The change of serum and urine TNF level and IL 2 receptor level in patients treated by intravesical instillation of pirarubicin alone or together with IL 2 were analysed.Results:Levels of TNF and IL 2 receptor were found to increase significantly after combined instillation of pirarubicin and IL 2( P <0.01).Conclusions:Intravesical instillation of pirarubicin together with IL 2 can improve cellular immunological function and IL 2 can improve immunological response of the tumor cells.
出处
《蚌埠医学院学报》
CAS
2001年第6期483-484,共2页
Journal of Bengbu Medical College
关键词
膀胱肿瘤
投药
吡柔比星
白细胞介素2
复发
bladder neoplasms
administration,intravesical
pirarubicin
interleukin 2(IL - 2)
